uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta Sells 28,341 Shares

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 28,341 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the transaction, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. This trade represents a 4.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

uniQure Trading Up 6.7 %

Shares of QURE stock opened at $12.09 on Thursday. The stock has a market cap of $589.30 million, a price-to-earnings ratio of -2.44 and a beta of 0.38. The stock has a 50-day moving average of $14.69 and a 200-day moving average of $9.91. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18.

Analysts Set New Price Targets

A number of brokerages recently commented on QURE. The Goldman Sachs Group lifted their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Cantor Fitzgerald raised their target price on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. Royal Bank of Canada restated an “outperform” rating and set a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. Wells Fargo & Company reduced their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a report on Friday, February 28th. Finally, Leerink Partners raised their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, uniQure has a consensus rating of “Moderate Buy” and a consensus target price of $38.89.

Institutional Investors Weigh In On uniQure

Several large investors have recently added to or reduced their stakes in QURE. Voloridge Investment Management LLC bought a new position in uniQure in the fourth quarter worth approximately $3,129,000. Woodline Partners LP bought a new position in uniQure in the fourth quarter worth approximately $2,484,000. Two Sigma Advisers LP boosted its holdings in uniQure by 1.4% in the fourth quarter. Two Sigma Advisers LP now owns 756,900 shares of the biotechnology company’s stock worth $13,367,000 after acquiring an additional 10,400 shares in the last quarter. Two Sigma Investments LP boosted its holdings in uniQure by 9.2% in the fourth quarter. Two Sigma Investments LP now owns 878,884 shares of the biotechnology company’s stock worth $15,521,000 after acquiring an additional 73,988 shares in the last quarter. Finally, Stempoint Capital LP bought a new position in uniQure in the fourth quarter worth approximately $1,589,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.